Cargando…
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Dysregulated signaling through the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways is often the result of genetic alterations in critical components in these pathways or upstream activators. Unrestricted cellular proliferation and decreased sensitivity to apoptotic-inducing agents are typically asso...
Autores principales: | Steelman, Linda S., Chappell, William H., Abrams, Stephen L., Kempf, C. Ruth, Long, Jacquelyn, Laidler, Piotr, Mijatovic, Sanja, Maksimovic-Ivanic, Danijela, Stivala, Franca, Mazzarino, Maria C., Donia, Marco, Fagone, Paolo, Malaponte, Graziella, Nicoletti, Ferdinando, Libra, Massimo, Milella, Michele, Tafuri, Agostino, Bonati, Antonio, Bäsecke, Jörg, Cocco, Lucio, Evangelisti, Camilla, Martelli, Alberto M., Montalto, Giuseppe, Cervello, Melchiorre, McCubrey, James A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3091517/ https://www.ncbi.nlm.nih.gov/pubmed/21422497 |
Ejemplares similares
-
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011) -
Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012) -
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012) -
Advances in Targeting Signal Transduction Pathways
por: McCubrey, James A., et al.
Publicado: (2012) -
Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
por: Chappell, William H., et al.
Publicado: (2020)